These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
667 related articles for article (PubMed ID: 27689408)
1. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N; Nakrani H; Raval M; Sheth N Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408 [TBL] [Abstract][Full Text] [Related]
2. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept. Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels. He W; Guo X; Feng M; Mao N Int J Pharm; 2013 Dec; 458(2):305-14. PubMed ID: 24409520 [TBL] [Abstract][Full Text] [Related]
4. Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing. Pathak MK; Chhabra G; Pathak K Drug Dev Ind Pharm; 2013 May; 39(5):780-90. PubMed ID: 22873799 [TBL] [Abstract][Full Text] [Related]
5. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217 [TBL] [Abstract][Full Text] [Related]
6. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Gratieri T; Gelfuso GM; de Freitas O; Rocha EM; Lopez RF Eur J Pharm Biopharm; 2011 Oct; 79(2):320-7. PubMed ID: 21641994 [TBL] [Abstract][Full Text] [Related]
7. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study. Singh J; Chhabra G; Pathak K Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522 [TBL] [Abstract][Full Text] [Related]
8. Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel. Cong Z; Shi Y; Peng X; Wei B; Wang Y; Li J; Li J; Li J Drug Dev Ind Pharm; 2017 Apr; 43(4):558-573. PubMed ID: 27935330 [TBL] [Abstract][Full Text] [Related]
9. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Kalam MA; Alshamsan A; Aljuffali IA; Mishra AK; Sultana Y Drug Deliv; 2016; 23(3):896-907. PubMed ID: 24865289 [TBL] [Abstract][Full Text] [Related]
10. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. Liu R; Liu Z; Zhang C; Zhang B J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401 [TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. Yang X; Trinh HM; Agrahari V; Sheng Y; Pal D; Mitra AK AAPS PharmSciTech; 2016 Apr; 17(2):294-306. PubMed ID: 26085051 [TBL] [Abstract][Full Text] [Related]
12. Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: In vitro drug release and in vivo tissue distribution. Wei Y; Li C; Zhu Q; Zhang X; Guan J; Mao S Int J Pharm; 2020 Mar; 578():119184. PubMed ID: 32112932 [TBL] [Abstract][Full Text] [Related]
13. Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38. Cavet ME; Glogowski S; Lowe ER; Phillips E J Ocul Pharmacol Ther; 2019 Jun; 35(5):291-300. PubMed ID: 30907685 [No Abstract] [Full Text] [Related]
14. [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. Shen JQ; Gan Y; Gan L; Zhu CL; Zhu JB Yao Xue Xue Bao; 2010 Jan; 45(1):120-5. PubMed ID: 21351461 [TBL] [Abstract][Full Text] [Related]
15. Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery. Noreen S; Ghumman SA; Batool F; Ijaz B; Basharat M; Noureen S; Kausar T; Iqbal S Int J Biol Macromol; 2020 Jun; 152():1056-1067. PubMed ID: 31751751 [TBL] [Abstract][Full Text] [Related]
16. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in-vitro characterization, statistical optimization, and in-vivo pharmacodynamic evaluation in rabbits. Fouda NH; Abdelrehim RT; Hegazy DA; Habib BA Drug Deliv; 2018 Nov; 25(1):1340-1349. PubMed ID: 29869516 [TBL] [Abstract][Full Text] [Related]
17. Prolonged Release Niosomes For Ocular Delivery of Loteprednol: Ocular Distribution Assessment on Dry Eye Disease Induced Rabbit Model. Ozdemir S; Uner B AAPS PharmSciTech; 2024 May; 25(5):119. PubMed ID: 38816667 [TBL] [Abstract][Full Text] [Related]
18. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate. Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220 [TBL] [Abstract][Full Text] [Related]
19. Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization, and in vitro-in vivo evaluation. Soliman OAE; Mohamed EA; Khatera NAA Pharm Dev Technol; 2019 Jan; 24(1):48-62. PubMed ID: 29210317 [TBL] [Abstract][Full Text] [Related]
20. Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery. Ammar HO; Salama HA; Ghorab M; Mahmoud AA Drug Dev Ind Pharm; 2010 Nov; 36(11):1330-9. PubMed ID: 20545523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]